{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:29:57Z","timestamp":1777577397179,"version":"3.51.4"},"reference-count":61,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIH-NIAID","doi-asserted-by":"publisher","award":["AI151765"],"award-info":[{"award-number":["AI151765"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Efficacy data on two malaria vaccines, RTS,S and R21, targeting Plasmodium falciparum circumsporozoite protein (PfCSP), are encouraging. Efficacy may be improved by induction of additional antibodies to neutralizing epitopes outside of the central immunodominant repeat domain of PfCSP. We designed four rPfCSP-based vaccines in an effort to improve the diversity of the antibody response. We also evaluated P. falciparum merozoite surface protein 8 (PfMSP8) as a malaria-specific carrier protein as an alternative to hepatitis B surface antigen. We measured the magnitude, specificity, subclass, avidity, durability, and efficacy of vaccine-induced antibodies in outbred CD1 mice. In comparison to N-terminal- or C-terminal-focused constructs, immunization with near full-length vaccines, rPfCSP (#1) or the chimeric rPfCSP\/8 (#2), markedly increased the breadth of B cell epitopes recognized covering the N-terminal domain, junctional region, and central repeat. Both rPfCSP (#1) and rPfCSP\/8 (#2) also elicited a high proportion of antibodies to conformation-dependent epitopes in the C-terminus of PfCSP. Fusion of PfCSP to PfMSP8 shifted the specificity of the T cell response away from PfCSP toward PfMSP8 epitopes. Challenge studies with transgenic Plasmodium yoelii sporozoites expressing PfCSP demonstrated high and consistent sterile protection following rPfCSP\/8 (#2) immunization. Of note, antibodies to conformational C-terminal epitopes were not required for protection. These results indicate that inclusion of the N-terminal domain of PfCSP can drive responses to protective, repeat, and non-repeat B cell epitopes and that PfMSP8 is an effective carrier for induction of high-titer, durable anti-PfCSP antibodies.<\/jats:p>","DOI":"10.3390\/vaccines12040351","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T12:40:11Z","timestamp":1711370411000},"page":"351","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design and Evaluation of Chimeric Plasmodium falciparum Circumsporozoite Protein-Based Malaria Vaccines"],"prefix":"10.3390","volume":"12","author":[{"given":"William H.","family":"Stump","sequence":"first","affiliation":[{"name":"Center for Molecular Parasitology, Department of Microbiology and Immunology, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley J.","family":"Klingenberg","sequence":"additional","affiliation":[{"name":"Center for Molecular Parasitology, Department of Microbiology and Immunology, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy C.","family":"Ott","sequence":"additional","affiliation":[{"name":"Center for Molecular Parasitology, Department of Microbiology and Immunology, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna M.","family":"Gonzales","sequence":"additional","affiliation":[{"name":"Center for Molecular Parasitology, Department of Microbiology and Immunology, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"James M.","family":"Burns","sequence":"additional","affiliation":[{"name":"Center for Molecular Parasitology, Department of Microbiology and Immunology, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(23)01249-7","article-title":"Malaria","volume":"402","author":"Poespoprodjo","year":"2023","journal-title":"Lancet"},{"key":"ref_2","unstructured":"Ghehreyesus, T. (2023). World Malaria Report 2023. Overview of Key Events in 2022\u20132023, World Health Organization."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1038\/s41467-022-30133-w","article-title":"Malaria in 2022: Increasing challenges, cautious optimism","volume":"13","author":"Jagannathan","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rabinovich, R.N., Drakeley, C., Djimde, A.A., Hall, B.F., Hay, S.I., Hemingway, J., Kaslow, D.C., Noor, A., Okumu, F., and Steketee, R. (2017). malERA: An updated research agenda for malaria elimination and eradication. PLoS Med., 14.","DOI":"10.1371\/journal.pmed.1002456"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","article-title":"Malaria Vaccines: Recent Advances and New Horizons","volume":"24","author":"Draper","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"eaau1458","DOI":"10.1126\/scitranslmed.aau1458","article-title":"Challenges and strategies for developing efficacious and long-lasting malaria vaccines","volume":"11","author":"Beeson","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1016\/j.vaccine.2015.09.093","article-title":"Recent advances in recombinant protein-based malaria vaccines","volume":"33","author":"Draper","year":"2015","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e156588","DOI":"10.1172\/JCI156588","article-title":"RTS,S: The first malaria vaccine","volume":"132","author":"Zavala","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: Secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ubillos, I., Ayestaran, A., Nhabomba, A.J., Dosoo, D., Vidal, M., Jimenez, A., Jairoce, C., Sanz, H., Aguilar, R., and Williams, N.A. (2018). Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S\/AS01E vaccination in African children. BMC Med., 16.","DOI":"10.1186\/s12916-018-1186-4"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"Rts","year":"2015","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gosling, R., and von Seidlein, L. (2016). The Future of the RTS,S\/AS01 Malaria Vaccine: An Alternative Development Plan. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1001994"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eabo6646","DOI":"10.1126\/scitranslmed.abo6646","article-title":"The RTS,S malaria vaccine: Current impact and foundation for the future","volume":"14","author":"Beeson","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: A phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: A randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: A multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"taad140","DOI":"10.1093\/jtm\/taad140","article-title":"R21\/Matrix-M malaria vaccine: A new tool to achieve WHO\u2019s goal to eliminate malaria in 30 countries by 2030?","volume":"30","author":"Genton","year":"2023","journal-title":"J. Travel Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1797","DOI":"10.1002\/hsr2.1797","article-title":"Unlocking the potential of novel RTS, S\/AS01, and R21\/Matrix-M malaria vaccines in African nations","volume":"7","author":"Oduoye","year":"2024","journal-title":"Health Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"Gordon","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"46621","DOI":"10.1038\/srep46621","article-title":"Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine","volume":"7","author":"Collins","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1016\/j.vaccine.2015.09.061","article-title":"RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap","volume":"33","author":"Kaslow","year":"2015","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm.4513","article-title":"A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein","volume":"24","author":"Tan","year":"2018","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","article-title":"A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver","volume":"53","author":"Wang","year":"2020","journal-title":"Immunity"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Flores-Garcia, Y., Wang, L.T., Park, M., Asady, B., Idris, A.H., Kisalu, N.K., Munoz, C., Pereira, L.S., Francica, J.R., and Seder, R.A. (2021). The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1010042"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/infdis\/jiv154","article-title":"Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies","volume":"212","author":"Espinosa","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.20101488","article-title":"The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host","volume":"208","author":"Coppi","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1128\/IAI.02676-14","article-title":"Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains","volume":"83","author":"Herrera","year":"2015","journal-title":"Infect. Immun."},{"key":"ref_29","first-page":"1248","article-title":"Heterologous Expression of Recombinant Proteins and Their Derivatives Used as Carriers for Conjugate Vaccines","volume":"88","author":"Khodak","year":"2023","journal-title":"Biochemistry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: Characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4049\/jimmunol.180.1.444","article-title":"Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and\/or challenge infection","volume":"180","author":"Petritus","year":"2008","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1128\/IAI.01467-06","article-title":"Enhanced protection against malaria by a chimeric merozoite surface protein vaccine","volume":"75","author":"Shi","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1128\/IAI.00211-12","article-title":"Evaluation of the Immunogenicity and Vaccine Potential of Recombinant Plasmodium falciparum Merozoite Surface Protein 8","volume":"80","author":"Alaro","year":"2012","journal-title":"Infect. Immun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1128\/IAI.00522-13","article-title":"A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies","volume":"81","author":"Alaro","year":"2013","journal-title":"Infect. Immun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12936-016-1226-5","article-title":"Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys","volume":"15","author":"Burns","year":"2016","journal-title":"Malar. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9022","DOI":"10.1038\/s41598-019-45440-4","article-title":"Immunization with merozoite surface protein 2 fused to a Plasmodium-specific carrier protein elicits strain-specific and strain-transcending, opsonizing antibody","volume":"9","author":"Eacret","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.4049\/jimmunol.2000927","article-title":"Inclusion of an Optimized Plasmodium falciparum Merozoite Surface Protein 2-Based Antigen in a Trivalent, Multistage Malaria Vaccine","volume":"206","author":"Eacret","year":"2021","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Parzych, E.M., Miura, K., Long, C.A., and Burns, J.M. (2020). Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0232355"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e00486-17","DOI":"10.1128\/IAI.00486-17","article-title":"Evaluation of a Plasmodium-Specific Carrier Protein to Enhance Production of Recombinant Pfs25, a Leading Transmission-Blocking Vaccine Candidate","volume":"86","author":"Parzych","year":"2018","journal-title":"Infect. Immun."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Angov, E., Hillier, C.J., Kincaid, R.L., and Lyon, J.A. (2008). Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002189"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2859-8-26","article-title":"Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli","volume":"8","year":"2009","journal-title":"Microb. Cell Factories"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26951","DOI":"10.1074\/jbc.M109.013706","article-title":"Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate","volume":"284","author":"Plassmeyer","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Coler, R.N., Bertholet, S., Moutaftsi, M., Guderian, J.A., Windish, H.P., Baldwin, S.L., Laughlin, E.M., Duthie, M.S., Fox, C.B., and Carter, D. (2011). Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016333"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2013.07.030","article-title":"Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis","volume":"172","author":"Orr","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0022-1759(86)90268-1","article-title":"Antibody avidity determination by ELISA using thiocyanate elution","volume":"86","author":"Pullen","year":"1986","journal-title":"J. Immunol. Methods"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12936-016-1248-z","article-title":"A highly infectious Plasmodium yoelii parasite, bearing Plasmodium falciparum circumsporozoite protein","volume":"15","author":"Zhang","year":"2016","journal-title":"Malar. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1016\/j.vaccine.2009.07.081","article-title":"Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion","volume":"27","author":"Baldwin","year":"2009","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/eji.201444543","article-title":"Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-\u03b3","volume":"45","author":"Desbien","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/eji.201243124","article-title":"MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant","volume":"43","author":"Orr","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41577-019-0158-z","article-title":"T cell-mediated immunity to malaria","volume":"19","author":"Kurup","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/21645515.2017.1381809","article-title":"Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine","volume":"14","author":"Moris","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.4049\/jimmunol.171.12.6961","article-title":"Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma","volume":"171","author":"Sun","year":"2003","journal-title":"J. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Beutler, N., Pholcharee, T., Oyen, D., Flores-Garcia, Y., MacGill, R.S., Garcia, E., Calla, J., Parren, M., Yang, L., and Volkmuth, W. (2022). A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010409"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","article-title":"Genetic Diversity and Protective Efficacy of the RTS,S\/AS01 Malaria Vaccine","volume":"373","author":"Neafsey","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.biochi.2010.06.001","article-title":"Identification of key residues involved in fibril formation by the conserved N-terminal region of Plasmodium falciparum merozoite surface protein 2 (MSP2)","volume":"92","author":"Yang","year":"2010","journal-title":"Biochimie"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/psc.910","article-title":"A partially structured region of a largely unstructured protein, Plasmodium falciparum merozoite surface protein 2 (MSP2), forms amyloid-like fibrils","volume":"13","author":"Yang","year":"2007","journal-title":"J. Pept. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1128\/IAI.00665-12","article-title":"Antigenic characterization of an intrinsically unstructured protein, Plasmodium falciparum merozoite surface protein 2","volume":"80","author":"Adda","year":"2012","journal-title":"Infect. Immun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41467-019-10195-z","article-title":"Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S\/AS01E malaria vaccine efficacy","volume":"10","author":"Dobano","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa2034031","article-title":"A Monoclonal Antibody for Malaria Prevention","volume":"385","author":"Gaudinski","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2206966","article-title":"Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali","volume":"387","author":"Kayentao","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2203067","article-title":"Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria","volume":"387","author":"Wu","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/4\/351\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:18:13Z","timestamp":1760105893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/4\/351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["vaccines12040351"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12040351","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]}}}